1. Source: Ours is produced by a yeast (not from mushroom or oats or barley); specifically, Aureobasidium Pullulans; Nichi Glucan and Nichi BRITE are from AFO-202 strain. Neu REFIX is from N-163 strain.
2.Production:Produced as an exo-polysaccharide by the specific strain of the yeast (not extracted or purified from mushroom, maitake or shiitake) in a GMP certified facility; Produced only in Japan.
3.Structure: Our beta-glucans have a unique molecular structure, unique compared to other Beta 1,3-1,6 glucans.
4.Water soluble: Ours is one of the few water-soluble products; easy to mix with food and consume.
5.Purity: The Beta-glucan available as active ingredient in our beta-glucans is in a much purer form (internal data)
6.Dosage standardization: Our product comes with standardized dosage because even the quantification of Beta glucan is our patented technology.
7.No need for cold storage: Our beta-glucans can be preserved in room temperature.
8.Gut microbiome balancing: Our products balance the gut microbiome not only by enhancing the good species but also by controlling the harmful ones which to our knowledge in clinical settings could be the first with safety.
9.Immune enhancement data: Has been thoroughly proven in pre-clinical, clinical in healthy volunteers, cancer patients (several types) and elderly people.
Publications
2025-04: Akira Tsukada, Isao Miyajima, Satomi Uchiyama,Daiki Tabe, Nobunao Ikewaki,
Koji Ichiyama, Rajappa Senthilkumar, Masaru Iwasaki, Samuel JK Abraham. Effects of Nichi BRITE Beta-Glucans as an onco-nutrition adjuvant in patients undergoing Subtotal stomach-preserving pancreaticoduodenectomy (SSPPD) for pancreatic, bile duct and duodenal malignancies; A clinical study. Science Direct | Nutrition. 2025;18. doi: 10.1016/j.nut.2025.112811
2025-03: Pushkala S, Seshayyan S, Theranirajan E, Sudhakar D, Raghavan K, Dedeepiya VD, Ikewaki N, Iwasaki M, Preethy S, Abraham SJK. Efficient control of IL-6, CRP and ferritin in COVID-19 patients with two variants of beta-1,3-1,6 glucans in combination: An open-label, prospective, randomised clinical trial. Global Advances in Integrative Medicine and Health. 2025;14. doi:10.1177/27536130251327134
2025-02: Ikewaki N, Ichiyama K, Senthilkumar R, Preethy S, Abraham SJK. Significance of neutrophil to lymphocyte ratio (NLR) and gut microbiome of astronauts during space missions and suggestions for beneficial modulations using novel beta-glucans. Front Immunol. 2025;16:1538147. doi:10.3389/fimmu.2025.1538147
2025-01: Preethy S, Sakamoto S, Higuchi T, Ichiyama K, Yamamoto N, Ikewaki N, Iwasaki M, Dedeepiya VD, Srinivasan S, Raghavan K, Rajmohan M, Senthilkumar R, Abraham SJK. Enhanced expression of dystrophin, IGF-1, CD44 and MYH3 in plasma and skeletal muscles including diaphragm of mdx mice after oral administration of Neu REFIX beta 1,3-1,6 glucan. Sci Rep. 2025;15:7232. doi:10.1038/s41598-025-07232-4.
2024-01: Ikewaki N, Ichiyama K, Rajappa S, Preethy S, Abraham SJK. Neutrophil-to-Lymphocyte Ratio (NLR) as a Critical Indicator of the ME-BYO Index and the Potential Role of Beta Glucans as a Modulator for Reversing ME-BYO Transitions to Disease States – Commentary on Nakamura, S., et al. (2023). Front Public Health. 2024;12:1495056. doi: 10.3389/fpubh.2024.1495056.
2023-08: Raghavan K, Sivakumar T, Ichiyama K, Yamamoto N, Balamurugan M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham S. Efficacy of N-163 beta-glucan in beneficially improving biomarkers of relevance to muscle function in patients with muscular dystrophies in a pilot clinical study. Acta Myologica 2023. 2023 Dec 20; doi: 10.36185/2532-1900-312
2023-07: Preethy S, Aoki Y, Minegishi K, Iwasaki M, Senthilkumar R, Abraham S. Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced β-glucan. Sci Rep 13, 17008 (2023). doi: 10.1038/s41598-023-44330-0
2023-06: Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N, Iwasaki M, Senthilkumar R, Preethy S, Abraham S. Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study. IBRO Neuroscience reports 2023; 15: 90-99. doi: 10.1016/j.ibneur.2023.06.007.
2023-05: Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham S . Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans exert immune and metabolic beneficial effects in healthy middle-aged Japanese men: Results of an exploratory randomized control study. J Aging Res & Lifestyle 2023;12:61-71. doi: 10.14283/jarlife.2023.11.
2023-04: Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Subramaniam Srinivasan, Subramanian Pushkala, Sudhakar S. Bharatidasan, Nobunao Ikewaki, Masaru Iwasaki, Rajappa Senthilkumar, Senthilkumar Preethy, Samuel J.K. Abraham. Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study. IBRO Neuroscience Reports 15 (2023) 90-99. doi : 10.1016/j.ibneur.2023.06.007.
2023-03: S Preethy , N Yamamoto , N Liem , S Bharatidasan , M Iwasaki , S Abraham . Role of gut microbiome homeostasis, integrity of the intestinal epithelial cells, and the (endogenous) butyrate in enduring a healthy long life. GEORGIAN MEDICAL NEWS
No 3 (336) 2023. Pubmed - PMID: 37166884.
2023-02:Samuel JK Abraham, Kadalraja Raghavan, Thanasekar Sivakumar, Sudhakar S Bharathidasan, Subramaniam Srinivasan, Vidyasagar Devaprasad Dedeepiya, Nobunao Ikewaki, Masaru Iwasaki, Rajappa Senthilkumar, Senthilkumar Preethy. Efficacy of a safe ß-glucan in improving muscle function in Duchenne Muscular Dystrophy; results of a 6-month nonrandomized open-label extension trial. MDA Conference 2023.
2023-01:Samuel JK Abraham, Shuji Sakamoto, Takuma Higuchi, Subramaniam Srinivasan, Vidyasagar Devaprasad Dedeepiya, Nobunao Ikewaki, Masaru Iwasaki, Mathaiyan Rajmohan, Rajappa Senthilkumar, Senthilkumar Preethy. Enhanced muscle regeneration in MDX Duchenne muscular dystrophy-mice, proven by CD44 & MYH3, on consumption of A.Pullulans produced Neu REFIX ß-Glucan.
MDA Conference 2023.
2022-08: Ikewaki N, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya VD, Rajmohan M, Suryaprakash V, Senthilkumar R, Preethy S. Abraham SJK. Beneficial effects of 1,3–1,6 β-glucans produced by Aureobasidium pullulans on non-esterified fatty acid levels in diabetic KKAy mice and their potential implications in metabolic dysregulation. J Diabetes Metab Disord (2022) doi: 10.1007/s40200-022-01170-5.
2022-07: Preethy S, Raghavan K, Ikewaki N, Abraham SJ. Qualitative Evaluation of α-Synuclein - A Critical Step in Unraveling the Complexities of Autism Spectrum Disorder. Med Princ Pract. 2022 Oct 29. doi: 10.1159/000527728.
2022-06: Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Sonoda T, Iwasaki M, Kandaswamy R, Senthilkumar R, Preethy S, Abraham SJK. Benefits of gut microbiota reconstitution by beta 1,3-1,6 glucans in subjects with autism spectrum disorder and other neurodegenerative diseases. Journal of Alzheimer's Disease.1 Jan. 2022 : 1 – 12. doi: 10.3233/JAD-220388
2022-05: Raghavan K, Dedeepiya VD, Kandaswamy R, Balamurugan M, Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Preethy S, Abraham SJK. Improvement of sleep patterns and serum melatonin levels in children with autism spectrum disorders after consumption of beta-1,3/1,6-glucan in a pilot clinical study. Brain and Behaviour. doi: 10.1002/brb3.2750
2022-04: Preethy S, Ikewaki N, Levy GA, Raghavan K, Dedeepiya VD, Yamamoto N, Srinivasan S, Ranganathan N, Iwasaki M, Senthilkumar R, Abraham SJK. RTwo unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential for applications in human health and disease. BMJ Open Gastroenterology 2022;9:e000985. doi: 10.1136/bmjgast-2022-000985
2022-03: Ikewaki N, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya VD, Rajmohan M, Suryaprakash V, Senthilkumar R, Preethy S. Abraham SJK. Beneficial effects of 1,3–1,6 β-glucans produced by Aureobasidium pullulans on non-esterified fatty acid levels in diabetic KKAy mice and their potential implications in metabolic dysregulation. J Diabetes Metab Disord (2022). doi: 10.1007/s40200-022-01170-5
2022-02: Ikewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya VD, Vaddi S, Senthilkumar R, Levy GA, Abraham SJK. Hepatoprotective effects of Aureobasidium pullulans derived Beta 1,3-1,6 biological response modifier glucans in a STAM- animal model of non-alcoholic steatohepatitis. Journal of Clinical and Experimental Hepatology.2022. doi: 10.1016/j.jceh.2022.06.008
2022-01: Raghavan K, Dedeepiya VD, Ikewaki N, Sonoda T, Iwasaki M, Preethy S, Abraham SJK. Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study. medRxiv 2021.06.28.21259619; doi: 10.1101/2021.06.28.21259619
2021-05: Ikewaki N, Raghavan K, Dedeepiya VD, Suryaprakash V, Iwasaki M, Preethy S, senthilkumar R, Abraham SJK.Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats. Clinical Immunology Communications 2021.
2021-04: Ikewaki N, Dedeepiya VD, Raghavan K, Rao K, Vaddi S, Osawa H, Kisaka T, Kurosawa G, Srinivasan S, Ganesakumar SRB, Senthilkumar R, Iwasaki M, Preethy S, Abraham SJK. β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review). Oncol Rep 47: 14, 2022 doi.org/10.3892/or.2021.8225
2021-03: Raghavan K, Dedeepiya VD, Suryaprakash V, Rao KS, Ikewaki N, Sonoda T, Levy GA, Iwasaki M, Senthilkumar R, Preethy S, Abraham SJK. Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study. Biomedicine & Pharmacotherapy, Article 112243, doi: 10.1101/2021.08.09.21261738
2021-02:Ikewaki N, Iwasaki M, Kurosawa G, Rao KS, Beitia JL, Preethy S, Abraham SJK. β-Glucans: Wide-spectrum Immune-balancing Food-supplement-based Enteric (β-WIFE) Vaccine Adjuvant Approach to COVID-19. Human Vaccines & Immunotherapeutics 2021; 17(9). doi:10.1080/21645515.2021.1880210.
2021-01:Ikewaki N, Dedeepiya VD, Iwasaki M, Abraham SJK. General Commentary: Beyond "TRIM" benefits of β-glucan by blood glucose and lipid balancing potentials in its defense Against COVID-19. doi: 10.3389/fimmu.2021.620658
2020-03:Rao K-S, Suryaprakash V, Senthilkumar R, Preethy S, Katoh S, Ikewaki N, Abraham SJK. Role of Immune Dysregulation in Increased Mortality Among a Specific Subset of COVID-19 Patients and Immune-Enhancement Strategies for Combatting Through Nutritional Supplements. Front. Immunol. 2020; 11:1548. doi: 10.3389/fimmu.2020.01548.
2020-02:Ikewaki N, Rao KS, Archibold AD, Iwasaki M, Senthilkumar R, Preethy S, Katoh S, Abraham SJK. Coagulopathy associated with COVID-19 – Perspectives & Preventive strategies using a Biological Response Modifier Glucan. Thromb J. 2020. doi: 10.1186/s12959-020-00239-6
2020-01:Ikewaki N, Iwasaki M, Abraham SJK. Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients. Journal of Diabetes & Metabolic Disorders 2020. doi: 10.1007/s40200-020-00664-4
2014-01:Ikewaki N, Iwasaki M, Abraham SJK. Beneficial effects of Black yeast derived 1-3, 1-6 beta glucan- Nichi Glucan in a dyslipidemic individual of Indian origin A case report. J Diet Suppl. 2014;11(1):1-6. doi:10.3109/19390211.2013.859211.
2012-01:Dedeepiya V, Sivaraman G,Venkatesh A, Preethy S, Abraham SJK. Potential Effects of Nichi Glucan as a Food Supplement for Diabetes Mellitus and Hyperlipidemia; Preliminary Findings from the Study on Three Patients from India. Case Reports in Medicine 2012 (2012), Article ID 895370;. doi:10.1155/2012/895370.
Preprints
Preprint 10: Preethy S, Aoki Y, Minegishi K, Iwasaki M, Senthilkumar R, Abraham S. Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced β-glucan. Scientific Reports 2023.
Preprint 09: Senthilkumar Preethy, Naoki Yamamoto, Kottoorathu Mammen Cherian, Rajasekaran Premsekar, Gary A Levy, Rajappa Senthilkumar, Samuel JK Abraham. Reduction in myocardial fibrosis in MDX mice on oral consumption of Aureobasidium Pullulans produced Neu REFIX Beta-glucans; holds potential as an adjuvant in managing post-transplantation organ fibrosis. biorxiv: 10.1101/2023.09.25.559276v1. doi : 10.1101/2023.09.25.559276.
Preprint 08: Senthilkumar Preethy, Shuji Sakamoto, Takuma Higuchi, Koji Ichiyama, Naoki Yamamoto, Nobunao Ikewaki, Masaru Iwasaki, Vidyasagar Devaprasad Dedeepiya, Subramaniam Srinivasan, Mathaiyan Rajmohan, Rajappa Senthilkumar, Samuel JK Abraham. Enhanced muscle regeneration in mdx mice, Duchenne muscular dystrophy animal model, proven by CD44 & MYH3 expression, on oral feeding of N-163 strain of Aureobasidium Pullulans produced B-Glucan. biorxiv 2023.06.06.543858v1 doi: 10.1101/2023.06.06.543858.
Preprint 07: Vidyasagar Devaprasad Dedeepiya, Chockanathan Vetrievel, Nobunao Ikewaki, Koji Ichiyama, Naoki Yamamoto, Hiroto Kawashima, Sudhakar S Bharatidasan, Subramaniam Srinivasan, Rajappa Senthilkumar, Senthilkumar Preethy, Samuel JK Abraham. Improvement in Expanded Disability Status Scale (EDSS) and anti-inflammatory parameters in patients with multiple sclerosis following oral consumption of N-163 strain of Aureobasidium pullulans produced beta glucan in a pilot clinical study. medRxiv 2023.05.14.23289953v2; doi: 10.1101/2023.05.14.23289953.
Preprint 06: Kadalraja Raghavan, Thanasekar Sivakumar, Sudhakar S Bharatidasan, Subramaniam Srinivasan, Vidyasagar Devaprasad Dedeepiya, Nobunao Ikewaki, Rajappa Senthilkumar, Senthilkumar Preethy, Samuel JK Abraham. Efficacy of N-163 strain of Aureobasidium pullulans-produced beta-glucan in improving muscle strength and function in patients with Duchenne muscular dystrophy; Results of a 6-month non-randomised open-label linear clinical trial. medRxiv 2023.04.29.23289260v1; doi: 10.1101/2023.04.29.23289260.
Preprint 05: Chockanathan Vetrievel, Allimuthu Nithyanandam, Subramaniam Srinivasan, Sudhakar S Bharatidasan, Vidyasagar Devaprasad Dedeepiya, Nobunao Ikewaki, Masaru Iwasaki, Rajappa Senthilkumar, Senthilkumar Preethy, Samuel JK Abraham. Evaluation of the disease modifying effects of Aureobasidium pullulans AFO 202 strain produced Beta Glucan in Parkinsons disease Results of a pilot clinical study. medRxiv 2023.04.14.23288571v1; doi: 10.1101/2023.04.14.23288571.
Preprint 04: Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Iwasaki M, Dinassing A, Senthilkumar R, Preethy S, Abraham SJK. QualitatRandomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: Favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation. medRxiv 2022.12.09.22283273; doi: 10.1101/2022.12.09.22283273.
Preprint 03: Preethy S, Aoki Y, Minegishi K, Iwasaki M, Senthilkumar R, Abraham S. Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced biological response modifier β-glucan (BRMG). bioRxiv 2022.; doi: 2022.11.17.516628
Preprint 02: Pushkala S, Seshayyan S, Theranirajan E, Sudhakar D, Raghavan K, Dedeepiya VD, Ikewaki N,Iwasaki M, Preethy S, Abraham S. Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial. medRxiv 2021.12.14.21267778; doi: 10.1101/2021.12.14.21267778
Preprint 01: Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham SJK. Immune and metabolic beneficial effects of Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-aged Japanese men: An exploratory study. medRxiv 2021.08.05.21261640; doi: 10.1101/2021.08.05.21261640
Presentations
8-10 Aug, 2024: Abraham S, Tsukada A, Miyajima I, Uchiyama S, Tabe D, Ikewaki N, Ichiyama K, Senthilkumar R, Iwasaki M. Effects of Aureobasidium Pullulans produced β-1,3-1,6-glucan on CA19-9, sCD44, IgA and sCD209 in patients undergoing surgical resection of malignant pancreatic tumors. (ASCO Breakthrough meeting abstract; Embargo till 08, August, 2024; J Clin Oncol 42, 2024 (suppl 23; abstr 96).
25, July 2024: Abraham S et al. Beneficial modulation of gut microbiome and Neutrophil-Lymphocyte ratio (NLR) by Nichi Glucan and its potentials as an adjuvant in malignant tumors of the pancreas and liver. 61st Annual Meeting of the Japanese Society of Surgical Metabolism and Nutrition. Osaka, Japan.
* Links to publications are posted for educational purposes only.